

In re application Darrell Sleep
U.S. National Phase Application
Based on Intl. Application No. PCT/GB2003/003273

Atty Docket No. P30,358 USA
January 21, 2005
Page 4


Amendments to the Claims

1. (Original) A polypeptide comprising

(i) a leader sequence, the leader sequence comprising

(a) a secretion pre sequence, and

(b) the following motif :



where X_1 is phenylalanine, tryptophan, or tyrosine, X_2 is isoleucine, leucine, valine, alanine or methionine, X_3 is leucine, valine, alanine or methionine, X_4 is serine or threonine and X_5 is isoleucine, valine, alanine or methionine ; and

(ii) a desired protein heterologous to the leader sequence.

2. (Original) A polypeptide according to Claim 1 wherein X_1 is phenylalanine.

3. (Currently amended) A polypeptide according to Claim 1 ~~or 2~~ wherein X_2 is isoleucine.

4. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding claims~~ wherein X_3 is valine.

In re application Darrell Sleep
U.S. National Phase Application
Based on Intl. Application No. PCT/GB2003/003273

Atty Docket No. P30,358 USA
January 21, 2005
Page 5

5. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding claims~~ wherein the amino acids of the motif are included in the polypeptide as substitutes, for naturally occurring amino acids.

6. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding claims~~ wherein X₅ is isoleucine.

7. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding claims~~ wherein the motif is -Phe-Ile-Val-Ser-Ile-.

8. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding claims~~ wherein the secretion pre sequence is an albumin secretion pre sequence or a variant thereof.

9. (Currently amended) A polypeptide according to Claim 8 wherein X₁, X₂, X₃, X₄ and X₅ are at positions -20, -19, -18, -17 and -16, respectively, in place of the naturally occurring amino acids at those positions, wherein the numbering is such that the -1 residue is the C-terminal amino acid of the native albumin secretion pro sequence and where X₁, X₂, X₃, X₄ and X₅ are amino acids as defined in ~~any one of Claims~~ Claim 1 to 7.

In re application Darrell Sleep
U.S. National Phase Application
Based on Intl. Application No. PCT/GB2003/003273

Atty Docket No. P30,358 USA
January 21, 2005
Page 6

10. (Currently amended) A polypeptide according to Claim ~~8~~ or 9 wherein the albumin secretion pre sequence or variant thereof is a human albumin secretion pre sequence or a variant thereof.

11. (Original) A polypeptide according to Claim 10 comprising the secretion pre sequence MKWVFIVSILFLFSSAYS.

12. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding claims~~ wherein the leader sequence comprises a secretion pro sequence.

13. (Currently amended) A polypeptide according to Claim 12 wherein the ~~albumin~~ secretion pre sequence or variant thereof is fused by a peptide bond at its C-terminal end to the N-terminal amino acid of a secretion pro sequence, or variant thereof, thereby to form a pre-pro sequence.

14. (Currently amended) A polypeptide according to Claim ~~12~~ or 13 wherein the secretion pro sequence is an albumin secretion pro sequence or variant thereof.

15. (Original) A polypeptide according to Claim 14 wherein the albumin secretion pro sequence is human serum albumin secretion pro sequence or variant thereof.

In re application Darrell Sleep
U.S. National Phase Application
Based on Intl. Application No. PCT/GB2003/003273

Atty Docket No. P30,358 USA
January 21, 2005
Page 7

16. (Currently amended) A polypeptide according to Claim ~~14~~ or 15 wherein the secretion pro sequence motif is the yeast MF α -1 secretion pro sequence or variant thereof.

17. (Original) A polypeptide according to Claim 12 comprising the sequence:

MKWVFIVSILFLFSSAYSRY¹Y²Y³Y⁴Y⁵

wherein Y¹ is Gly or Ser, Y² is Val or Leu, Y³ is Phe or Asp, Y⁴ is Arg or Lys and Y⁵ is Arg or Lys, or variants thereof.

18. (Original) A polypeptide according to Claim 17 wherein Y¹ is Gly, Y² is Val and Y³ is Phe; or Y¹ is Ser, Y² is Leu and Y³ is Asp.

19. (Currently amended) A polypeptide according to Claim 17 ~~or 18~~ wherein Y⁴ is Arg and Y⁵ is Arg; Y⁴ is Lys and Y⁵ is Arg; Y⁴ is Lys and ~~Y~~ Y⁵ is Lys; or Y⁴ is Arg and Y⁵ is Lys.

20. (Currently amended) A polypeptide according to Claim 1 ~~any one of claims 1 to 7~~ wherein at least part of said motif is present in the secretion pre-sequence.

21. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding~~

In re application Darrell Sleep
U.S. National Phase Application
Based on Intl. Application No. PCT/GB2003/003273

Atty Docket No. P30,358 USA
January 21, 2005
Page 8

~~claims~~ wherein the sequence of the desired protein is fused at its N-terminal end to the C-terminal amino acid of the leader sequence.

22. (Currently amended) A polypeptide according to Claim 1 ~~any one of the preceding claims~~ where the desired protein is albumin or a variant, fragment or fusion thereof.

23. (Original) A polypeptide according to Claim 22 wherein the albumin is human albumin.

24. (Currently amended) A polypeptide according to ~~any one of Claims 1 to Claim 21~~ wherein the mature polypeptide is transferrin or a variant, fragment or fusion thereof.

25. (Original) A polypeptide according to Claim 24 wherein the transferrin is human transferrin.

26. (Currently amended) An isolated polynucleotide comprising a sequence that encodes the motif defined by Claim 1 ~~any preceding claim~~.

27. (Original) A polynucleotide according to Claim 26 comprising the sequence of SEQ ID No. 15.

In re application Darrell Sleep
U.S. National Phase Application
Based on Intl. Application No. PCT/GB2003/003273

Atty Docket No. P30,358 USA
January 21, 2005
Page 9

28. (Original) A polynucleotide according to Claim 26 comprising the sequence of SEQ ID No. 16.

29. (Original) A polynucleotide according to Claim 26 comprising the sequence of SEQ ID No. 17.

30. (Original) A polynucleotide according to Claim 26 comprising the sequence of SEQ ID No. 18.

31. (Original) A polynucleotide according to Claim 26 comprising the sequence of SEQ ID No. 34.

32. (Currently amended) A polynucleotide according to Claim 30 ~~or 31~~ comprising the sequence of SEQ ID No. 24.

33. (Original) A polynucleotide according to Claim 32 comprising the sequence of SEQ ID No. 25 or a variant thereof, which variant has the leader sequence of SEQ ID No. 24 and encodes a variant or fragment of the albumin encoded by SEQ ID No. 25.

In re application Darrell Sleep
U.S. National Phase Application
Based on Intl. Application No. PCT/GB2003/003273

Atty Docket No. P30,358 USA
January 21, 2005
Page 10

34. (Currently amended) A polynucleotide according to Claim 30 ~~or 31~~ comprising the sequence of SEQ ID No. 27.

35. (Original) A polynucleotide according to Claim 34 comprising the sequence of SEQ ID No. 21 or a variant thereof, which variant has the leader sequence of SEQ ID No. 27 and encodes a variant or fragment of the albumin encoded by SEQ ID No. 21.

36. (Original) A polynucleotide comprising the sequence of SEQ ID No. 21 or fragment thereof.

37. (Currently amended) A polynucleotide according to any one of Claim ~~Claims~~ 33, 35 ~~or 36~~ wherein the polynucleotide comprises a DNA sequence being a contiguous or non-contiguous fusion of a DNA sequence encoding a heterologous protein with either the DNA sequence SEQ ID No. 25 or the DNA sequence SEQ ID No. 21.

38. (Currently amended) A polynucleotide which is the complementary strand of a polynucleotide according to ~~any one of claims~~ Claim 26 ~~to 37~~.

39. (Currently amended) A polynucleotide according to ~~any one of Claims~~ Claim 26 to 38 comprising an operably linked transcription regulatory region.

In re application Darrell Sleep
U.S. National Phase Application
Based on Intl. Application No. PCT/GB2003/003273

Atty Docket No. P30,358 USA
January 21, 2005
Page 11

40. (Original) A polynucleotide according to Claim 39 wherein the transcription regulatory region comprises a transcription promoter.

41. (Currently amended) A self-replicable polynucleotide sequence comprising a polynucleotide according ~~any one of Claims~~ to Claim 26 ~~to 40~~.

42. (Currently amended) A cell comprising a polynucleotide according to ~~any one of Claims~~ Claim 26 ~~to 41~~.

43. (Original) A cell according to Claim 42 which is a eukaryotic cell.

44. (Original) A cell according to Claim 43 which is a fungal cell.

45. (Original) A cell according to Claim 44 which is an *Aspergillus* cell

46. (Original) A cell according to Claim 44 which is a yeast cell.

47. (Original) A cell according to Claim 46 which is a *Saccharomyces*, *Kluyveromyces*, *Schizosaccharomyces* or *Pichia* cell.

In re application Darrell Sleep
U.S. National Phase Application
Based on Intl. Application No. PCT/GB2003/003273

Atty Docket No. P30,358 USA
January 21, 2005
Page 12

48. (Currently amended) A cell culture comprising a cell according to ~~any one of Claims~~
Claim 42 to 47 and culture medium.

49. (Currently amended) A cell culture according to Claim 48 wherein the medium
contains a mature desired protein as a result of the production of a polypeptide as defined
in ~~any one of Claims~~ Claim 1 to 22.

50. (Currently amended) A process for producing a mature desired protein, comprising
(1) culturing a cell according to ~~any one of Claims~~ Claim 42 to 47 in a culture medium
wherein the cell, as a result of the production of a polypeptide as defined in ~~any one of~~
~~Claims~~ Claim 1 to 25, secretes a mature desired protein into the culture medium, and (2)
separating the culture medium, containing the secreted mature protein, from the cell.

51. (Currently amended) A process according to Claim 50 additionally comprising the
step of separating the mature desired protein from the medium ~~and optionally further~~
~~purifying the mature desired protein~~.

52. (Currently amended) A process according to Claim 51 additionally comprising the
step of formulating the ~~thus separated and/or purified~~ mature desired protein with a

In re application Darrell Sleep
U.S. National Phase Application
Based on Intl. Application No. PCT/GB2003/003273

Atty Docket No. P30,358 USA
January 21, 2005
Page 13

therapeutically acceptable carrier or diluent thereby to produce a therapeutic product suitable for administration to a human or an animal.

53. (New) A polynucleotide according to any one of Claim ~~Claims 33, 35 or 36~~ wherein the polynucleotide comprises a DNA sequence being a contiguous or non-contiguous fusion of a DNA sequence encoding a heterologous protein with either the DNA sequence SEQ ID No. 25 or the DNA sequence SEQ ID No. 21.

54. (New) A polynucleotide according to any one of Claim ~~Claims 33, 35 or 36~~ wherein the polynucleotide comprises a DNA sequence being a contiguous or non-contiguous fusion of a DNA sequence encoding a heterologous protein with either the DNA sequence SEQ ID No. 25 or the DNA sequence SEQ ID No. 21.

55. (New) A process according to Claim 51 additionally comprising the step of further purifying the mature desired protein.

56. (New) A process according to Claim 55 additionally comprising the step of formulating the thus separated and purified mature desired protein with a therapeutically acceptable carrier or diluent thereby to produce a therapeutic product suitable for administration to a human or an animal.